Therapy for myeloproliferative neoplasms: when, which agent, and how?

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia, and myelofibrosis (MF), present significant symptom burdens, complications, and leukemia progression risks.
• Recent diagnostic and prognostic advancements in MPNs have driven the development of targeted therapies.
• Existing therapies like ruxolitinib have demonstrated efficacy in managing MF symptoms, splenomegaly, and quality of life.

Purpose of the Study:

• To review the evolving data and role of JAK inhibition in managing patients with MPNs.
• To discuss the expanding clinical applications and ongoing investigations of JAK2 inhibitors.
• To highlight current and future therapeutic strategies for MF and PV.

Main Methods:

• Review of current clinical trial data and therapeutic advancements in MPN management.
• Focus on JAK inhibitors, including established agents and investigational compounds.
• Exploration of combination therapies and novel pathway targets.

Main Results:

• JAK inhibition, exemplified by ruxolitinib, has proven effective in alleviating symptoms and improving quality of life in MF.
• Ongoing trials are evaluating new JAK inhibitors (e.g., pacritinib, momelotinib) for MF, aiming for reduced myelosuppression and improved anemia management.
• Therapeutic evolution in PV includes investigating optimal frontline treatments and the role of JAK inhibitors in refractory or intolerant cases.

Conclusions:

• JAK inhibition, both as monotherapy and in combination, is a cornerstone in the evolving management of MPNs.
• Continued research into novel JAK inhibitors and combination strategies holds promise for further improving patient outcomes in MF and PV.
• The expanding role of JAK inhibition underscores its significance in addressing the complexities of these clonal hematologic malignancies.